Titre
Hippo/YAP pathway for targeted therapy.
Type
synthèse (review)
Institution
Externe
Périodique
Auteur(s)
Felley-Bosco, E.
Auteure/Auteur
Stahel, R.
Auteure/Auteur
Liens vers les personnes
ISSN
2218-6751
Statut éditorial
Publié
Date de publication
2014
Volume
3
Numéro
2
Première page
75
Dernière page/numéro d’article
83
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Review Publication Status: ppublish
Résumé
Malignant pleural mesothelioma (MPM) is molecularly characterized by loss of function or mutations in the neurofibromin 2 (NF2) and the cyclin-dependent kinase inhibitor 2 genes. NF2 activates a cascade of kinases, called Hippo pathway, which downregulates Yes associated protein (YAP) function as transcription co-activator for TEA domain transcription factors (TEAD). In the absence of functional NF2, the expression of genes essential for cell cycling such as survivin is increased. New therapeutic strategies aimed at interfering with YAP activity include inhibition of hedgehog pathway, which downregulates the YAP protein, verteporfin, which inhibits the assembly of a functional YAP-TEAD transcription factor, and interference with thrombin and lysophosphatidic acid (LPA) receptors downstream signalling, since upon agonist binding they activate YAP.
PID Serval
serval:BIB_343AE36E29C2
PMID
Date de création
2015-08-12T06:42:16.037Z
Date de création dans IRIS
2025-05-20T17:55:02Z